Menu
1 min read · estimated
APPROVED USE
What FDA approved
Patients with hepatocellular carcinoma caused by hepatitis B who have received prior systemic therapy other than a PD-1 or PD-L1 inhibitor-containing regimen.
LAMPGEN ANALYSIS
Why it matters
Traditional approval followed confirmatory review and revised the previously accelerated indication to a hepatitis B-associated population.
What research teams should watch
Record tumor etiology and prior checkpoint exposure and coordinate hepatitis B treatment and liver laboratory monitoring.
PRIMARY RECORDS